A prospective study on impact of patient counselling on quality of life of patients with atopic dermatitis


  • Ranjeth R. Pharm. D Intern, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
  • Resmi Vijayasenan Pharm. D Intern, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
  • Amritha M. S. Pharm. D Intern, Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India
  • I. John Wesley Department of Pharmacy Practice, Sree Krishna College of Pharmacy and Research Centre, Parassala, Thiruvananthapuram, Kerala, India




Atopic dermatitis, DLQI, QoL


Background: Atopic dermatitis is an acute, sub-acute or chronic relapsing skin disorder characterized by intense itching, pruritus and oozing. It adversely affects the routine activities of patients for which effective treatment is to be provided along with proper counselling. The aim of the current study was to evaluate the impact of patient counselling on quality of life (QoL).

Methods: A prospective study was conducted in 108 patients recruited from the Department of Dermatology for a period of 6 months. A written informed consent was taken. Out of the 108 patients, 54 patients received tacrolimus and the remaining received corticosteroids. The collected data was analysed and presented. Data was collected by using a suitably designed proforma. Dermatology life quality index (DLQI) was used for assessing QoL. Patients were counselled regarding the disease, drugs and lifestyle modifications using patient information leaflet (PIL).

Results: The current study found that patient counselling was effective for both the groups with a p value <0.05. The effect of disease in quality of life improved from severe to mild in both groups (prior to counselling QoL mean value of 2.93±0.61 shifted to 1.18±0.71 post counselling). In the tacrolimus group, QoL mean value of 2.81±0.61 shifted to 0.98±0.71 after counselling. In the corticosteroids group, a shift from a mean QoL value of 3.05±0.59 to a mean of 1.38±0.65 was observed post counselling.

Conclusions: The provision of effective counselling was found to have a profound impact on improving patient’s quality of life. A transition from severe effects of the disease to milder effects of the disease on quality of life was observed.


Sardana K, Khurana A, Mahajan K, Bhole A. Atopic Dermatitis. Handbook of Eczema for Dermatologists. 2nd Edition. CBS Publishers; 2019.

Darsow U, Lübbe J, Taieb A, Seidenari S, Wollenberg A, Calza AM, et al. Position on the diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2005;19:286-95.

Williams H. Atopic dermatitis. N Engl J Med. 2005;352:2314-24.

Brown S, Reynolds NJ. Atopic and non-atopic eczema. BMJ. 2006;332:584-8.

Aoki T, Fukuzumi T, Adachi J, Endo K, Kojima M. Re-evaluation of skin lesion distribution in atopic dermatitis. Analysis of cases 0 to 9 years of age. Acta Derm Venereol Suppl (Stockh). 1992;176:19-23.

Macharia WM, Anabwani GM, Owili DM. Clinical presentation of atopic dermatitis in Negroid children. Afr J Med Sci. 1993;22:414.

Waersted A, Hjorth N. Pityrosporum orbiculare- a pathogenetic factor in the atopic dermatitis of the face, scalp and neck. Acta Derm Venereol Suppl (Stockh). 1985;114:46-8.

Dold S, Wjst M, Von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. Arch Dis Childhood. 1992;67(8):1018-22.

Ruiz RG, Kemeny DM, Price JF. Higher risk of infantile atopic dermatitis from- maternal atopy than from paternal atopy. Clin Exp Allerg. 1992;22:762-6.

Ohman S. Johanason SG. Allergen-specific IgE in atopic dermatitis. Acta Derm Venereol. 1974;54:283-90.

Grewe M, Walther S, Gyufko K, Czech W, Schöpf E, Krutmann J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Investigat Dermatol. 1995;105(3):407-10.

Thepen T, Langeveld-Wildschut EG, Bihari IC, van Wichen DF, van Reijsen FC, Mudde GC, et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allerg Clin Immunol. 1996;97(3):828-37.

Zachary CB, Allen MH, MacDonald DM. In situ quantification of T-lymphocytes subsets and Langerhans cells in the inflammatory infiltrate of atopic eczema. Br J Dermatol. 1985;112:149-56.

Lever R, Turbitt M, Sanderson A, Mackie R. Immunophenotyping of the cutaneous infiltrate and of the mononuclear cells in the peripheral blood in patients with atopic dermatitis. J Investigat Dermatol. 1987;89(1):4-7.

Grimalt R, Mengeaud V, Cambazard F. The steroid sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology (Basel). 2007;214:61-7.

Juhlin L, Johansson SG, Bennich H, Höugman C, Thyresson N. Immunoglobulin E levels in atopic dermatitis, urticaria, and various dermatoses. Arch Dermatol. 1969;100:12-6.

Schmid P, Simon D, Simon HU, Akdis CA, Wüthrich B. Epidemiology, clinical features, and immunology of the “intrinsic” (non‐IgE‐mediated) type of atopic dermatitis (constitutional dermatitis). Allergy. 2001;56(9):841-9.

Hanifin JM, Rajka RG. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;92(144):44-7.

Finlay AY, Khan GK. The dermatology life quality index: a simple practical measure for routine clinical use. British Association of Dermatologists Annual Meeting. Oxford. Br J Dermatol. 1993;129(42):27.

Finlay AY. Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994:210-6.

Cardiff University Department Of Dermatology. Available form: https://www.cardiff.ac.uk/medicine/ resources/quality-of-life-questionnaires/dermatology-life-quality-index

Mozaffari H, Pourpak Z, Farhoodi A, Aghamohammadi A, Movahadi M, Gharaghozloo M, et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect. 2007;40(3):260-4.

Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39:42-7.

Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis is associated with a decrement in health related quality of life. Int J Dermatol. 2002;41:151-8.

Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol. 1995;63:624-35.

Jasper JPC, Span L, Molier L, Coenraads PJ. A multimodal education and treatment program for young adults with atopic dermatitis: a randomized controlled trial. Dermatol Psychosom. 2000;1:148-53.

Gieler U, Kupfer J, Neimeier V, Brosig B, Standier U. Atopic eczema prevention programs- a new therapeutic concept for secondary prevention. Dermatol Psychosom. 2000;1:138-47.

Chida Y, Steptoe A, Hirakawa N, Sudo N, Kubo C. The effects of psychological intervention on atopic dermatitis. A systemic review and meta-analysis. Int Arch Allerg Immunol. 2007;144:1-9

Linnet J, Jemec GBE. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol. 1999;140:268-72.

Schmidt-Ott G, Kuensebeck HW, Jaeger B, Werfel T, Frahm K, Ruitman J, et al. Validity study of the stigmatization experience in atopic and psoriatic patients. Acta Derm Venereol. 1999;79:443-7.

Habib S, Morrissey S. Stress management for atopic dermatitis. Behav Change. 1999;16(4):226-36.




How to Cite

R., R., Vijayasenan, R., S., A. M., & Wesley, I. J. (2020). A prospective study on impact of patient counselling on quality of life of patients with atopic dermatitis. International Journal of Basic & Clinical Pharmacology, 9(12), 1860–1865. https://doi.org/10.18203/2319-2003.ijbcp20205123



Original Research Articles